Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet

British Journal of Pharmacology

Volumn 128, Issue 3, 1999, Pages 523-529

  Miyazaki, Mizuo ^a   Sakonjo, Hiroshi ^a,b   Takai, Shinji ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b Environmental Biological Life Science Research Center Inc   (Japan)

Author keywords

Angiotensin II; Antagonist; Atherosclerosis; Inhibitor; Monkey

Indexed keywords

2 BUTYL 4 METHYLTHIO 1 [[2' [[[(PROPYLAMINO)CARBONYL]AMINO]SULFONYL][1,1' BIPHENYL] 4 YL]METHYL] 1H IMIDAZOLE 5 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN II ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; RENIN; TRANDOLAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; MALE; MEAN ARTERIAL PRESSURE; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; THORACIC AORTA;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA; ARTERIOSCLEROSIS; BIPHENYL COMPOUNDS; CHOLESTEROL, DIETARY; FEMALE; IMIDAZOLES; INDOLES; MACACA FASCICULARIS; MALE; PEPTIDYL-DIPEPTIDASE A;

EID: 0032719311     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702833     Document Type: Article

References (48)

1. ABERG, G. & FERRER, P. (1990). Effets of captopril on atherosclerosis in cynomolgus monkeys. J. Cardiovasc. Pharmacol., 15 (Suppl), S65-S72.
2. BELZ, G.G., ESSIG, J., KLEINBLOESEM, C.H., HOOGKAMER, J.F., WIEGAND, U.W. & WELLSTEIN, A. (1988). Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex. Br. J. Clin. Pharmacol., 26, 547-556.
3. BLUMLEIN, S.L., SIEVERS, R., KIDD, P. & PARMLEY, W.W. (1984). Mechanism of protection from atherosclerosis by verapamil in the cholesterol-fed rabbit. Am. J. Cardiol., 54, 884-889.
4. BROWN, N L., BADEL, M.Y., BENZONI, F., ZANIRATO, J., VINCENT, J.C., FICHELLE, J. & WORCEL, M. (1988). Angiotensin-converting enzyme inhibition, anti-hypertensive activity and hemodynamic profile of trandolapril (RU 44570). Eur. J. Pharmacol., 148, 79-91.
5. BRUNEVAL, P., HINGLAIS, N., ALHENC-GELAS, F., TRICOTTET, V., CORVOL, P., MENARD, J., CAMILLERI, J.P. & BARIETY, J. (1986). Angiotensin I converting enzyme in human intestine and kidney. Ultrastructual immunohistochemical locarization. Histochemistry, 85, 73-80.
6. CATALANO, R.A. & LILLIE, R.D. (1975). Elimination of precipitates in oil red O fat stain by adding dextrin. Stain Technol., 50, 297-299.
7. CHOBANIAN, A.V., HAUDENSCHILD, C.C., NICKERSON, C. & DRAGO, R. (1990). Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension, 15, 327-331.
8. CHOBANIAN, A.V., HAUDENSCHILD, C.C., NICKERSON, C. & HOPE, S. (1992). Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbits. Hypertension, 20, 473-477.
9. CHOBANIAN, A.V., HOPE, S. & BRECHER, P. (1995). Dissociation between the antiatherosclerotic effect of trandolapril and suppression of serum and aortic angiotensin-converting enzyme activity in the Watanabe heritable hyperlipidemic rabbit. Hypertension, 25, 1306-1310.
10. FINTA, K.M., FISCHER, M.J., LEE, L., GORDON, D., PITT, B. & WEBB, R.C. (1993). Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet. Atherosclerosis, 100, 149-156.
11. GIANNATTASIO, C., CATTANEO, B.M., OMBONI, S., SERAVALLE, G., BOLLA, G., TUROLO, L., MORGANTI, A., GRASSI, G., ZANCHETTI, A. & MANCIA, G. (1992). Sympathomoderating influence of benazepril in essential hypertension. J. Hypertens., 10, 373-378.
12. GIBBONS, G.H., PRATT, R.E. & DZAU, V.J. (1992). Vascular smooth muscle cell hypertrophy vs hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J. Clin. Invest., 90, 456-461.
13. ITOH, H., MUKOYAMA, M., PRATT, R.E., GIBBONS, G.H. & DZAU, V.J. (1993). Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J. Clin. Invest., 91, 2268-2274.
14. JACOBSSON, L.S., PERSSON, K., ABERG, G., ANDERSSON, R.G., KARLBERG, B.E. & OLSSON, A.G. (1994). Antiatherosclerotic effects of the angiotensin-converting enzyme inhibitors captopril and fosinopril in hypercholesterolemic minipigs. J. Cardiovasc. Pharmacol., 24, 670-677.
15. JIN, D., SONG, K., OKA, Y., TAKAI, S., SHIOTA, N. & MIYAZAKI, M. (1997). Pharmacological Profiles of a novel non-peptide angiotensin II type I receptor antagonist HR720 in vitro and in vivo. Jpn. J. Pharmacol., 75, 259-266.
16. KEIDAR, S. (1998). Angiotensin, LDL peroxidation and atherosclerosis. Life Sci., 63, 1-11.
17. KIM, S., TOKUYAMA, M., HOSOI, M. & YAMAMOTO, K. (1992). Adrenal and circulating renin-angiotensin system in stroke-prone hypertensive rats. Hypertension, 20, 280-291.
18. KOWALA, M.C., VALENTINE, M., RECCE, R., BEYER, S., GOLLER, N., DURHAM, S. & ABERG, G. (1998). Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and captopril: ACE in atheromas provides cellular targets for captopril. J. Cardiovasc. Pharmacol., 32, 29-38.
19. LAIBERTE, F., LAIBERTE, M.F., ALHENC-GELAS, F. & CHEVILLARD, C. (1987). Cellular and subcellular immunohistochemical in the rat adrenal gland. Lab. Invest., 56, 364-371.
20. LA VILLE, A.E., SEDDON, A., SHAIKH, M., ROWLES, P.M., WOOLF, N. & LEWIS, B. (1989). Primary prevention of atherosclerosis by lovastatin in a genetically hyperlipidaemic rabbit strain. Atherosclerosis. 78, 205-210.
21. LINDPAINTNER, K., JIN, M., WILHELM, M., TOTH, M & GANTEN D. (1989). Aspects of molecular biology and biochemistry of the cardiac renin-angiotensin system. Br. J. Clin. Pharmacol., 27 (Suppl), S159-S165.
22. LINZ, W., WIEMER, G., GOHLKE, P., UNGER, T. & SCHOLKENS, B.A. (1995). Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev., 47, 25-49.
23. LINZ, W. WIEMER, G. & SCHOLKENS, B.A. (1993). Contribution of bradykinin to the cardiovascular effects of ramipril. J. Cardiovasc. Pharmacol., 22 (Suppl), S1-S8.
24. MIDDEKE, M. & HOLZGREVE, H. (1998). Review of major intervention studies in hypertension and hyperlipidemia: focus on coronary heart disease. Am. Heart. J., 116, 1708-1712.
25. MILLER, N.E. (1982). Coronary atherosclerosis and plasma lipoproteins: epidemiology and pathophysiologic considerations. J. Cardiovasc. Pharmacol., 4 (Suppl), S190-S195.
26. MITANI, H., BANDOH, T., KIMURA, M., TOTSUKA, T. & HAYASHI, S. (1996). Increased activity of vascular ACE related to atherosclerotic lesions in hyperlipidemic rabbits. Am. J. Physiol., 271, H1065-H1071.
27. MIYAZAKI, M., OKUNISHI, H., NISHIMURA, K. & TODA, N. (1984). Vascular angiotensin-converting enzyme activity in man and other species. Clin. Sci., 66, 39-45.
28. MIYAZAKI, M., WADA, T., SHIOTA, N. & TAKAI, S. (1999). Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury. J. Hum. Hypertens. 12 (Suppl), S21-S25.
29. NAFTILAN, A.J., GILLILAND, G.K., ELDRIDGE, C.S. & KRAFT, A.S. (1990). Induction of the proto-oncogene c-jun by angiotensin II. Mol. Cell. Biol., 10, 5536-5540.
30. NISHIZONO, S., KUSABA, M., ADAN, Y. & IMAIZUMI, K. (1999). Induction of atherosclerosis in brown Norway rats by immunization with ovalbumin. Biosci. Biotechnol. Biochem., 63, 379-383.
31. NOMA, A., NEZU-NAKAYAMA, K., KITA, M. & OKABE, H. (1978). Simultaneous determination of serum cholesterol in high-and low-density lipoproteins with use of heparin, Ca2+, and an anion-exchange resin. Clin. Chem., 24, 1504-1508.
32. RICHMOND, W. (1976). Use of cholesterol oxidase for assay of total and free cholesterol in serum by continuous-flow analysis. Clin. Chem., 22, 1579-1588.
33. RIEZEBOS, J., VLEEMING, W., BEEMS, R.B., VAN AMSTERDAM, J.G., MEIJER, G.W., DE WILDT, D.J., PORSIUS, A.J. & WEMER, J. (1994a). Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: I. Effect on progression of atherosclerosis and endothelial dysfunction. J. Cardiovasc. Pharmacol., 23, 415-423.
34. RIEZEBOS, J., VLEEMING, W., BEEMS, R.B., VAN AMSTERDAM, J.G., MEIJER, G.W., DE WILDT, D.J., PORSIUS, A.J. & WEMER, J. (1994b). Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: II. Effect on regression of atherosclerosis and restoration of endothelial function. J. Cardiovasc. Pharmacol., 23, 424-431.
35. SASAKI, S., YONEDA, Y., FUJITA, H., UCHIDA, A., TAKENAKA, K., TAKESAKO T., ITOH, H., NAKATA, T., TAKEDA, K. & NAKAGAWA, M. (1994). Association of blood pressure variability with induction of atherosclerosis in cholesterol-fed rats. Am. J. Hypertens., 7, 453-459.
36. SCHUH, J.R., BLEHM, D.J., FRIERDICH, G.E., MCMAHON, E.G. & BLAINE, E.H. (1993). Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J. Clin. Invest., 91, 1453-1458.
37. SEIGLER, I., & WU, W.T. (1981). Separation of serum high-density lipoprotein for cholesterol determination: ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin. Chem., 27, 838-841.
38. SHIBOUTA, Y., INADA, Y., OJIMA, M., WADA, T., NODA, M., SANADA, T., KUBO, K., KOHARA, Y., NAKA, T. & NISHIKAWA, K. (1993). Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-telrazol-5-yl) biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[ [2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J. Pharmacol. Exp. Ther., 266, 114-120.
39. SONG, K., SHIOTA, N., TAKAI, S., TAKASHIMA, H., IWASAKI, H., KIM, S. & MIYAZAKI M. (1998). Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed Cynomolgus monkeys. Atherosclerosis, 138, 171-182.
40. SPENCE, J.D., PESOUT, A.B. & MELMON, K.L. (1977). Effects of antihypertensive drugs on blood velocity in rhesus monkeys. Stroke, 8, 589-594.
41. STEINBERG, D., CAREW, T.E., FIELDING, C., FOGELMAN, A.M., MAHLEY, R.W., SNIDERMAN, A.D. & ZILVERSMIT, D.B. (1989). Lipoproteins and the pathogenesis of atherosclerosis. Circulation, 80, 719-723.
42. TAKAI, S., SHIOTA, N., KOBAYASHI, S., MATSUMURA, E. & MIYAZAKI, M. (1997a). Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett., 412, 86-90.
43. TAKAI, S., SHIOTA, N., SAKAGUCHI, M., MURAGUCHI, H., MATSUMURA, E. & MIYAZAKI, M. (1997b). Characterization of chymase from human vascular tissues. Clin. Chim. Acta., 265, 13-20.
44. UJHELYI, M.R., FERGUSON, R.K. & VLASSES, P.H. (1989). Angiotensin-converting enzyme inhibitors: mechanistic controversies. Pharmacotherapy, 9, 351-362.
45. WATANABE, Y., ITO, T., SHIOMI, M., TSUJITA, Y., KURODA, M., ARAI, M., FUKAMI, M. & TAMURA, A. (1988). Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits. Biochim. Biophys. Acta., 960, 294-302.
46. WIEMER, G., SCHOLKENS B.A., BECKER, R.H. & BUSSE, R. (1991). Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension, 18, 558-563.
47. WITZTUM, J.L. (1994). The role of oxidized LDL in the atherogenic process. J. Atheroscler. Thromb., 1, 71-75.
48. YANG, H.Y., ERDOS, E.G. & LEVIN, Y. (1971). Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme). J. Pharmacol. Exp. Ther., 177, 291-300.